RxDoctor Payments Data

Danielle McVeigh

Nurse Practitioner · Hattiesburg, MSNPI 1699230193

Payments from drug & device makers

$4,418in general payments, 2019–2025

Across 226 payments — averaging $19.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$631
  • Boehringer Ingelheim$483
  • Merck$263
  • AstraZeneca$209
  • Atricure, Inc.$144
  • plus $895 from 15 others

What the payments were for

  • Food & beverage$4,418100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,418 in reported general payments places this provider in the 90th percentile of 1,090 nurse practitioner providers in Mississippi.

See all nurse practitioner providers in Mississippi

Medicare billing

Part B allowed, 2024
$85,046
Medicare patients
714
Services billed
1,885

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban157$118,910
XareltoRivaroxaban44$31,941
EntrestoSacubitril/Valsartan27$23,860
BrilintaTicagrelor37$20,045
JardianceEmpagliflozin21$13,138
FarxigaDapagliflozin Propanediol16$8,098
Repatha SureclickEvolocumab11$5,873
Metoprolol Succinate224$2,032
Amiodarone Hcl73$1,163
ClopidogrelClopidogrel Bisulfate159$1,059
Nitroglycerin34$907
Isosorbide Mononitrate ErIsosorbide Mononitrate115$899
Atorvastatin Calcium113$760
Ranolazine ErRanolazine18$734
Flecainide Acetate23$609

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$54$118,910157 claims
Johnson & JohnsonXarelto$77$31,94144 claims
AstraZenecaBrilinta, Farxiga$209$28,14453 claims
NovartisEntresto$1,793$23,86027 claims
Boehringer IngelheimJardiance$483$13,13821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,090 nurse practitioner providers in Mississippi.

Other nurse practitioner in Hattiesburg

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →